Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
11 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 43(2); June 2011
Prev issue Next issue
Review Article
The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms
Max Dahele, Suresh Senan
Cancer Res Treat. 2011;43(2):75-82.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.75
AbstractAbstract PDFPubReaderePub
A compelling body of non-randomized evidence has established stereotactic ablative lung radiotherapy (SABR) as a standard of care for medically inoperable patients with peripheral early-stage non-small cell lung cancer (NSCLC). This convenient outpatient therapy, which is typically delivered in 3-8 fractions, is also well tolerated by elderly and frail patients, makes efficient use of resources and is feasible using standard commercial equipment. The introduction of lung SABR into large populations has led to an increased utilization of radiotherapy, a reduction in the proportion of untreated patients and an increase in overall survival. In selected patients, the same ablative technology can now achieve durable local control of NSCLC metastases in a variety of common locations including the adrenal glands, bone, brain, and liver. At the same time as this, advances in prognostic molecular markers and targeted systemic therapies mean that there is now a subgroup of patients with stage IV NSCLC and a median survival of around 2 years. This creates opportunities for new trials that incorporate SABR and patient-specific systemic strategies. This selective mini-review focuses on the emerging role of SABR in patients with early-stage and oligometastatic NSCLC.

Citations

Citations to this article as recorded by  
  • Navigating patient journey in early diagnosis of lung cancer in India
    Bivas Biswas, Deepak Talwar, Priti Meshram, Pramod K. Julka, Anurag Mehta, SP Somashekhar, Srinivas Chilukuri, Abhishek Bansal
    Lung India.2023; 40(1): 48.     CrossRef
  • Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers
    Lydia P. Liew, Avik Shome, Way W. Wong, Cho R. Hong, Kevin O. Hicks, Stephen M. F. Jamieson, Michael P. Hay
    Molecules.2023; 28(11): 4457.     CrossRef
  • Breast Metastasis of Lung Cancer After Computed Tomography-Guided Core Needle Biopsy: A Case Report
    Rong Zhao, Jun Xing, Jinnan Gao
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative” intent
    Michela Buglione, Barbara Alicja Jereczek-Fossa, Marco Lorenzo Bonù, Davide Franceschini, Andrei Fodor, Isa Bossi Zanetti, Marianna Alessandra Gerardi, Paolo Borghetti, Davide Tomasini, Nadia Gisella Di Muzio, Olga Oneta, Marta Scorsetti, Ciro Franzese, P
    Lung Cancer.2020; 141: 1.     CrossRef
  • Staging Lung Cancer
    Girish S. Shroff, Chitra Viswanathan, Brett W. Carter, Marcelo F. Benveniste, Mylene T. Truong, Bradley S. Sabloff
    Radiologic Clinics of North America.2018; 56(3): 411.     CrossRef
  • Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer: A Primer for Radiologists
    Jennifer A. Febbo, Ramya S. Gaddikeri, Palmi N. Shah
    RadioGraphics.2018; 38(5): 1312.     CrossRef
  • Preliminary comparison of the registration effect of 4D-CBCT and 3D-CBCT in image-guided radiotherapy of Stage IA non–small-cell lung cancer
    Zhibo Tan, Chuanyao Liu, Ying Zhou, Weixi Shen
    Journal of Radiation Research.2017; 58(6): 854.     CrossRef
  • Narcissus, the Beam, and lung cancer
    Gaetano Rocco
    The Journal of Thoracic and Cardiovascular Surgery.2016; 152(2): 338.     CrossRef
  • Efficacy of stereotactic radiotherapy for brain metastases using dynamic jaws technology in the helical tomotherapy system
    Taro Murai, Akihiro Hayashi, Yoshihiko Manabe, Chikao Sugie, Taiki Takaoka, Takeshi Yanagi, Tetsuya Oguri, Masayuki Matsuo, Yoshimasa Mori, Yuta Shibamoto
    The British Journal of Radiology.2016; 89(1066): 20160374.     CrossRef
  • Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
    Erik O. Pettersen, Peter Ebbesen, Roben G. Gieling, Kaye J. Williams, Ludwig Dubois, Philippe Lambin, Carol Ward, James Meehan, Ian H. Kunkler, Simon P. Langdon, Anne H. Ree, Kjersti Flatmark, Heidi Lyng, Maria J. Calzada, Luis del Peso, Manuel O. Landazu
    Journal of Enzyme Inhibition and Medicinal Chemistry.2015; 30(5): 689.     CrossRef
  • Monte Carlo validation of the TrueBeam 10XFFF phase–space files for applications in lung SABR
    Tony Teke, Cheryl Duzenli, Alanah Bergman, Francis Viel, Parmveer Atwal, Ermias Gete
    Medical Physics.2015; 42(12): 6863.     CrossRef
  • Stratégies d’évaluation de la réponse après irradiation stéréotaxique des cancers bronchiques primitifs et des métastases pulmonaires
    I. Barillot, O. Munier, M. Hatime, F. Mornex
    Cancer/Radiothérapie.2014; 18(4): 308.     CrossRef
  • Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer
    Sivan M. Bokobza, Yanyan Jiang, Anika M. Weber, Aoife M. Devery, Anderson J. Ryan
    International Journal of Radiation Oncology*Biology*Physics.2014; 88(4): 947.     CrossRef
  • Can an alternative backround-corrected [18F] fluorodeoxyglucose (FDG) standard uptake value (SUV) be used for monitoring tumor local control following lung cancer stereotactic body radiosurgery?
    Charles Shang, Michael Kasper, Vindu Kathriarachchi, Rashmi Benda, Joseph Kleinman, Jeremy Cole, Timothy Williams
    International Journal of Cancer Therapy and Oncology.2014; 2(3): 020317.     CrossRef
  • Stereotactic ablative body radiotherapy combined with immunotherapy: Present status and future perspectives
    N.H. Rekers, E.G.C. Troost, C.M.L. Zegers, W.T.V. Germeraad, L.J. Dubois, P. Lambin
    Cancer/Radiothérapie.2014; 18(5-6): 391.     CrossRef
  • Cáncer de pulmón
    P. Resano Barrio, Y. Anta Mejía
    Medicine - Programa de Formación Médica Continuada Acreditado.2014; 11(67): 3983.     CrossRef
  • Increasing Use of Advanced Radiation Therapy Technologies in the Last 30 Days of Life Among Patients Dying As a Result of Cancer in the United States
    B. Ashleigh Guadagnolo, Kai-Ping Liao, Sharon H. Giordano, Linda S. Elting, Thomas A. Buchholz, Ya-Chen Tina Shih
    Journal of Oncology Practice.2014; 10(4): e269.     CrossRef
  • Extra-thoracic tumor burden but not thoracic tumor burden on 18F-FDG PET/CT is an independent prognostic biomarker for extensive-disease small cell lung cancer
    Jong-Ryool Oh, Ji-Hyoung Seo, Chae Moon Hong, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Jung-Joon Min, Ho-Chun Song, Hee-Seung Bom, Young-Chul Kim, Byeong-Cheol Ahn
    Lung Cancer.2013; 81(2): 218.     CrossRef
  • Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States
    B. Ashleigh Guadagnolo, Jinhai Huo, Kai‐Ping Liao, Thomas A. Buchholz, Prajnan Das
    Cancer.2013; 119(5): 1089.     CrossRef
  • Escaping death to quiescence: Avoiding mitotic catastrophe after DNA damage
    Zhiyuan Shen, Steven C. Huhn, Bruce G. Haffty
    Cell Cycle.2013; 12(11): 1664.     CrossRef
  • CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer
    B.A. Jereczek-Fossa, I. Bossi-Zanetti, R. Mauro, G. Beltramo, L. Fariselli, L.C. Bianchi, C. Fodor, P. Fossati, G. Baroni, R. Orecchia
    Strahlentherapie und Onkologie.2013; 189(6): 448.     CrossRef
  • The development of stereotactic body radiotherapy (SBRT) for medically inoperable early stage non-small cell lung cancer: an international phenomenon
    Gregory M. M. Videtic
    Journal of Radiation Oncology.2012; 1(1): 3.     CrossRef
  • Improving lung cancer survival; time to move on
    Marlies E Heuvers, Joost P Hegmans, Bruno H Stricker, Joachim G Aerts
    BMC Pulmonary Medicine.2012;[Epub]     CrossRef
  • Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A systematic review of the literature
    Kitty Huang, Max Dahele, Suresh Senan, Matthias Guckenberger, George B. Rodrigues, Aaron Ward, R. Gabriel Boldt, David A. Palma
    Radiotherapy and Oncology.2012; 102(3): 335.     CrossRef
  • 12,880 View
  • 103 Download
  • 24 Crossref
Close layer
Original Articles
Gastric Cancer Screening in Korea: Report on the National Cancer Screening Program in 2008
Kyung Sook Lee, Dong Kwan Oh, Mi Ah Han, Hoo-Yeon Lee, Jae Kwan Jun, Kui Son Choi, Eun-Cheol Park
Cancer Res Treat. 2011;43(2):83-88.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.83
AbstractAbstract PDFPubReaderePub
PURPOSE
The National Cancer Screening Program (NCSP) began in 1999. The objective of this report is to evaluate the results of the NCSP in 2008 and provide essential evidence associated with the gastric cancer screening program in Korea.
MATERIALS AND METHODS
Data was obtained from the National Cancer Screening Information System; participation rates in gastric cancer screening were calculated. According to screening modalities, recall rates were estimated with 95% confidence intervals (CIs).
RESULTS
The target population of the gastric cancer screening program in 2008 was 7,132,820 Korean men and women aged 40 and over, 2,076,544 of whom underwent upper endoscopy or upper gastrointestinal (UGI) series as screening tools (participation rate, 29.1%). Disparities in participation rates were observed relating to gender and health insurance type. Overall, recall rates of upper endoscopy and UGI series were 3.1% (95% CI, 3.0 to 3.1) and 33.3% (95% CI, 33.3 to 33.4), respectively.
CONCLUSION
According to our research, efforts to facilitate participation and to reduce disparities in gastric cancer screening among Korean men and women are needed. These results will provide essential data for evidence-based strategies in gastric cancer control in Korea.

Citations

Citations to this article as recorded by  
  • Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer
    Zhishan Zhang, Jinyuan Huang, Yingying Li, Huimeng Yan, Junxing Xie, Jing Wang, Bin Zhao
    Aging.2024;[Epub]     CrossRef
  • Endoscopic Submucosal Dissection in the Stomach and Duodenum
    Sarah S. Al Ghamdi, Saowanee Ngamruengphong
    Gastrointestinal Endoscopy Clinics of North America.2023; 33(1): 67.     CrossRef
  • A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When?
    Wladyslaw Januszewicz, Maryla Helena Turkot, Peter Malfertheiner, Jaroslaw Regula
    Cancers.2023; 15(3): 664.     CrossRef
  • Determination of an Appropriate Endoscopic Monitoring Interval for Patients with Gastric Precancerous Conditions in China
    Kai Zhao, Li-na Feng, Su-hong Xia, Wang-dong Zhou, Ming-yu Zhang, Yu Zhang, Ruo-nan Dong, De-an Tian, Mei Liu, Jia-zhi Liao
    Current Medical Science.2023; 43(2): 268.     CrossRef
  • How to Improve the Efficacy of Gastric Cancer Screening?
    Wladyslaw Januszewicz, Maryla Helena Turkot, Jaroslaw Regula
    Current Treatment Options in Gastroenterology.2023; 21(3): 241.     CrossRef
  • Role of geographic characteristics in the spatial cluster detection of cancer: Evidence in South Korea, 1999–2013
    Insang Song, Eun-Hye Yoo, Inkyung Jung, Jin-Kyoung Oh, Sun-Young Kim
    Environmental Research.2023; 236: 116841.     CrossRef
  • Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer
    Astrid E. Slagter, Irene A. Caspers, Nicole C. T. van Grieken, Iris Walraven, Pehr Lind, Elma Meershoek-Klein Kranenbarg, Cecile Grootscholten, Marianne Nordsmark, Johanna W. van Sandick, Karolina Sikorska, Cornelis J. H. van de Velde, Edwin P. M. Jansen,
    Cancers.2022; 14(12): 2963.     CrossRef
  • Chinese and Global Burdens of Gastrointestinal Cancers From 1990 to 2019
    Wangcheng Xie, Tingsong Yang, Jieliang Zuo, Zhilong Ma, Weidi Yu, Zhengyu Hu, Zhenshun Song
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis
    Sen Hou, Fan Liu, Zhidong Gao, Yingjiang Ye
    World Journal of Surgical Oncology.2022;[Epub]     CrossRef
  • Disparate and Alarming Impact of Gastrointestinal Cancers in Young Adult Patients
    Amir Khan, Philip H. G. Ituarte, Mustafa Raoof, Laleh Melstrom, Haiqing Li, Yate-Ching Yuan, Lily Lai, I. Benjamin Paz, Ajay Goel, Yuman Fong, Yanghee Woo
    Annals of Surgical Oncology.2021; 28(2): 785.     CrossRef
  • Implementation effect of institutional policy of EGD observation time on neoplasm detection
    Jae Myung Park, Sang Yoon Kim, Ga-Yeong Shin, Younghee Choe, Hyun Sun Cho, Chul-Hyun Lim, Yu Kyung Cho, Myung-Gyu Choi
    Gastrointestinal Endoscopy.2021; 93(5): 1152.     CrossRef
  • Periodic Fluctuations in the Incidence of Gastrointestinal Cancer
    Mun-Gan Rhyu, Jung-Hwan Oh, Tae Ho Kim, Joon-Sung Kim, Young A Rhyu, Seung-Jin Hong
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Disparities in gastric cancer screening among people with disabilities: a national registry-linkage study in South Korea
    YoungJee Kim, Dong Wook Shin, Hyoung Woo Kim, Jin Hyung Jung, Kyungdo Han, In Young Cho, So Young Kim, Kui Son Choi, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi
    Gastric Cancer.2020; 23(3): 497.     CrossRef
  • Analysis of lymph node metastasis in early gastric cancer: a single institutional experience from China
    Jinggui Chen, Guangfa Zhao, Yanong Wang
    World Journal of Surgical Oncology.2020;[Epub]     CrossRef
  • Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035
    Melina Arnold, Jin Young Park, M Constanza Camargo, Nuno Lunet, David Forman, Isabelle Soerjomataram
    Gut.2020; 69(5): 823.     CrossRef
  • Surveillance Endoscopy Guidelines for Postgastrectomy Patients Based on Risk of Developing Remnant Gastric Cancer
    Eui Soo Han, Ho Seok Seo, Ji Hyun Kim, Han Hong Lee
    Annals of Surgical Oncology.2020; 27(11): 4216.     CrossRef
  • Global burden of oesophageal and gastric cancer by histology and subsite in 2018
    Melina Arnold, Jacques Ferlay, Mark I van Berge Henegouwen, Isabelle Soerjomataram
    Gut.2020; 69(9): 1564.     CrossRef
  • Towards Personalization in the Curative Treatment of Gastric Cancer
    Astrid E. Slagter, Marieke A. Vollebergh, Edwin P. M. Jansen, Johanna W. van Sandick, Annemieke Cats, Nicole C. T. van Grieken, Marcel Verheij
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Community-Based Pilot Study of a Screening Program for Gastric Cancer in a Chinese Population
    Lin Ji, Zengchao Liu, Bin Zhou, Ying Cai, Fangmei An, Lei Wang, Zhifa Lv, Min Xia, Jianbo Yang, Jianfen Yuan, Hui Wang, Zhiyi Zhou, Shudong Yang, Lei Hu, Qiang Zhan
    Cancer Prevention Research.2020; 13(1): 73.     CrossRef
  • The incidence of lymph node metastasis in submucosal early gastric cancer according to the expanded criteria: a systematic review
    Mohamed M. Abdelfatah, Mohamed Barakat, Mohamed O. Othman, Ian S. Grimm, Noriya Uedo
    Surgical Endoscopy.2019; 33(1): 26.     CrossRef
  • Efficacy and safety of endoscopic submucosal dissection for gastric epithelial neoplasia in elderly patients aged 80 years and older
    Young Woong Son, Ain Kim, Han Ho Jeon
    Aging Clinical and Experimental Research.2019; 31(12): 1833.     CrossRef
  • Quality of Life in Vietnamese Gastric Cancer Patients
    Dzung Ngoc Thi Dang, Lan Ngoc Thi Nguyen, Nga Thi Dang, Huy Quang Dang, Thanh Van Ta
    BioMed Research International.2019; 2019: 1.     CrossRef
  • The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis
    Mohamed M. Abdelfatah, Mohamed Barakat, Hyuk Lee, Jae J. Kim, Noriya Uedo, Ian Grimm, Mohamed O. Othman
    Gastrointestinal Endoscopy.2018; 87(2): 338.     CrossRef
  • Aplicación de la endoscopia sistemática alfanumérica codificada más cromoendoscopia para la detección de lesiones precancerosas gástricas y cáncer gástrico temprano en sujetos con riesgo promedio de cáncer gástrico
    A. Pérez-Mendoza, Á.M. Zárate-Guzmán, E.S. Galvis García, S. Sobrino Cossío, J. Djamus Birch
    Revista de Gastroenterología de México.2018; 83(2): 117.     CrossRef
  • Non‐alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study
    Yang Won Min, Youngha Kim, Geum‐Youn Gwak, Seonhye Gu, Danbee Kang, Soo Jin Cho, Eliseo Guallar, Juhee Cho, Dong Hyun Sinn
    Journal of Gastroenterology and Hepatology.2018; 33(5): 1053.     CrossRef
  • Endoscopic Treatment for Esophageal Cancer
    Yang Won Min
    The Korean Journal of Gastroenterology.2018; 71(3): 116.     CrossRef
  • The Effect ofHelicobacter pyloriInfection on the Recurrence of Gastric Hyperplastic Polyp
    Su Youn Nam
    The Korean Journal of Gastroenterology.2018; 71(4): 183.     CrossRef
  • Effect of Helicobacter pylori eradication on the regression of gastric polyps in National Cancer Screening Program
    Su Youn Nam, Bum Joon Park, Kum Hei Ryu, Ji Hyung Nam
    The Korean Journal of Internal Medicine.2018; 33(3): 506.     CrossRef
  • Endoscopic submucosal dissection under general anesthesia for superficial esophageal squamous cell carcinoma is associated with better clinical outcomes
    Byeong Geun Song, Yang Won Min, Ra Ri Cha, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee, Poong-Lyul Rhee, Jae J. Kim
    BMC Gastroenterology.2018;[Epub]     CrossRef
  • Systematic alphanumeric-coded endoscopy versus chromoendoscopy for the detection of precancerous gastric lesions and early gastric cancer in subjects at average risk for gastric cancer
    A. Pérez-Mendoza, Á.M. Zárate-Guzmán, E.S. Galvis García, S. Sobrino Cossío, J. Djamus Birch
    Revista de Gastroenterología de México (English Edition).2018; 83(2): 117.     CrossRef
  • Occurrence of gastric cancer in patients with atrophic gastritis during long-term follow-up
    Liming Zhang, Yulan Liu, Peng You, Guijian Feng
    Scandinavian Journal of Gastroenterology.2018; 53(7): 843.     CrossRef
  • Comparison of endoscopic submucosal dissection and surgery for superficial esophageal squamous cell carcinoma: a propensity score-matched analysis
    Yang Won Min, Hyuk Lee, Byeong Geun Song, Byung-Hoon Min, Hong Kwan Kim, Yong Soo Choi, Jun Haeng Lee, Na-Young Hwang, Keumhee C. Carriere, Poong-Lyul Rhee, Jae J. Kim, Jae Ill Zo, Young Mog Shim
    Gastrointestinal Endoscopy.2018; 88(4): 624.     CrossRef
  • Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer
    Feng Li, Janice M Yoshizawa, Kyoung-Mee Kim, Julie Kanjanapangka, Tristan R Grogan, Xiaoyan Wang, David E Elashoff, Shigeo Ishikawa, David Chia, Wei Liao, David Akin, Xinmin Yan, Min-Sun Lee, Rayun Choi, Su-Mi Kim, So-Young Kang, Jae-Moon Bae, Tae-Sung So
    Clinical Chemistry.2018; 64(10): 1513.     CrossRef
  • Endoscopic prediction model for differentiating upper submucosal invasion (< 200 μm) and beyond in superficial esophageal squamous cell carcinoma
    Joohwan Bae, In Seub Shin, Yang Won Min, Insuk Sohn, Joong Hyun Ahn, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee, Poong-Lyul Rhee, Jae J. Kim
    Oncotarget.2018; 9(10): 9156.     CrossRef
  • Differences in upper gastrointestinal neoplasm detection rates based on inspection time and esophagogastroduodenoscopy training
    Shoichi Yoshimizu, Toshiaki Hirasawa, Yusuke Horiuchi, Masami Omae, Akiyoshi Ishiyama, Toshiyuki Yoshio, Tomohiro Tsuchida, Junko Fujisaki
    Endoscopy International Open.2018; 06(10): E1190.     CrossRef
  • Endoscopic Management of Early Gastric Adenocarcinoma and Preinvasive Gastric Lesions
    Saowanee Ngamruengphong, Seiichiro Abe, Ichiro Oda
    Surgical Clinics of North America.2017; 97(2): 371.     CrossRef
  • Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality
    Jae Kwan Jun, Kui Son Choi, Hoo-Yeon Lee, Mina Suh, Boyoung Park, Seung Hoon Song, Kyu Won Jung, Chan Wha Lee, Il Ju Choi, Eun-Cheol Park, Dukhyoung Lee
    Gastroenterology.2017; 152(6): 1319.     CrossRef
  • Evaluation of Transabdominal Ultrasound with Oral Cellulose-Based Contrast Agent in the Detection and Surveillance of Gastric Ulcer
    Zhijun Liu, Jintao Guo, Shupeng Wang, Ying Zhao, Zhining Liu, Jing Li, Weidong Ren, Shaoshan Tang, Limei Xie, Ying Huang, Siyu Sun, Liping Huang
    Ultrasound in Medicine & Biology.2017; 43(7): 1364.     CrossRef
  • Longer Observation Time Increases Proportion of Neoplasms Detected by Esophagogastroduodenoscopy
    Jae Myung Park, Sol Mi Huo, Han Hee Lee, Bo-In Lee, Ho Jin Song, Myung-Gyu Choi
    Gastroenterology.2017; 153(2): 460.     CrossRef
  • Risk Factors for Gastric Tumorigenesis in Underlying Gastric Mucosal Atrophy
    Ji Hyun Song, Sang Gyun Kim, Eun Hyo Jin, Joo Hyun Lim, Sun Young Yang
    Gut and Liver.2017; 11(5): 612.     CrossRef
  • Belching during gastroscopy and its association with gastroesophageal reflux disease
    B. S. Lee, S. H. Lee, D. K. Jang, K. H. Chung, J. H. Hwang, S. E. Jang, B. H. Cha, J. K. Ryu, Y.-T. Kim
    Diseases of the Esophagus.2016; 29(4): 342.     CrossRef
  • Endoscopic and oncologic outcomes according to indication criteria of endoscopic resection for early gastric cancer: a systematic review and meta-analysis
    Se Woo Park, Hyuk Lee, Chan Hyuk Park, Hyun Joo Jang, Hongyup Ahn
    Surgical Endoscopy.2016; 30(4): 1270.     CrossRef
  • The risk of lymph node metastases in 3951 surgically resected mucosal gastric cancers: implications for endoscopic resection
    Kang Kook Choi, Jae Moon Bae, Su Mi Kim, Tae Sung Sohn, Jae Hyung Noh, Jun Ho Lee, Min-Gew Choi, Sung Kim
    Gastrointestinal Endoscopy.2016; 83(5): 896.     CrossRef
  • The Influence of Gastric Cancer Screening on the Stage at Diagnosis and Survival
    Esha Khanderia, Sheraz R. Markar, Amish Acharya, Yeol Kim, Young-Woo Kim, George B. Hanna
    Journal of Clinical Gastroenterology.2016; 50(3): 190.     CrossRef
  • Differences in routine esophagogastroduodenoscopy between Japanese and international facilities: A questionnaire survey
    Noriya Uedo, Takuji Gotoda, Shigetaka Yoshinaga, Tokuma Tanuma, Yoshinori Morita, Hisashi Doyama, Akira Aso, Toshiaki Hirasawa, Tomonori Yano, Norihisa Uchita, Shiaw‐Hooi Ho, Ping‐Hsin Hsieh
    Digestive Endoscopy.2016; 28(S1): 16.     CrossRef
  • Current Perspectives on Gastric Cancer
    Juan M. Marqués-Lespier, María González-Pons, Marcia Cruz-Correa
    Gastroenterology Clinics of North America.2016; 45(3): 413.     CrossRef
  • Meta‐analysis of confocal laser endomicroscopy for the diagnosis of gastric neoplasia and adenocarcinoma
    Wei Qian, Tao Bai, Huan Wang, Lei Zhang, Jun Song, Xiao Hua Hou
    Journal of Digestive Diseases.2016; 17(6): 366.     CrossRef
  • Endoscopic Submucosal Dissection Outcomes for Gastroesophageal Tumors in Low Volume Units: A Multicenter Survey
    Ahmad Najib Azmi, Christopher J. L. Khor, Khek-Yu Ho, Rapat Pittayanon, Rungsun Rerknimitr, Thawee Ratanachu-ek, Doreen S. C. Koay, Jianyi Calvin Koh, Shiaw-Hooi Ho, Khean-Lee Goh, Sanjiv Mahadeva
    Diagnostic and Therapeutic Endoscopy.2016; 2016: 1.     CrossRef
  • Cost Comparison between Surgical Treatments and Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer in Korea
    Younhee Kim, Young-Woo Kim, Il Ju Choi, Joo Young Cho, Jong Hee Kim, Jin-Won Kwon, Ja Youn Lee, Na Rae Lee, Sang-Yong Seol
    Gut and Liver.2015; 9(2): 174.     CrossRef
  • Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine
    Yoon Young Choi, Sung Hoon Noh, Jae-Ho Cheong
    Yonsei Medical Journal.2015; 56(5): 1177.     CrossRef
  • Antifungal Treatment is Not Required for Immunocompetent Individuals With Asymptomatic Esophageal Candidiasis
    Yang Won Min, Eun Kim, Hee Jung Son, Jae J. Kim, Poong-Lyul Rhee
    Medicine.2015; 94(45): e1969.     CrossRef
  • Evaluation of transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent for gastric cancer
    Zhijun Liu, Jintao Guo, Shupeng Wang, Ying Zhao, Jing Li, Weidong Ren, Shaoshan Tang, Limei Xie, Ying Huang, Siyu Sun, Liping Huang
    BMC Cancer.2015;[Epub]     CrossRef
  • Biopathologic features and clinical significance of micrometatasis in the lymph node of early gastric cancer
    Min Jung Jo
    World Journal of Gastroenterology.2015; 21(2): 667.     CrossRef
  • ESD Around the World: United States
    Norio Fukami
    Gastrointestinal Endoscopy Clinics of North America.2014; 24(2): 313.     CrossRef
  • Screening of Gastric Cancer: Who, When, and How
    Jaw–Town Lin
    Clinical Gastroenterology and Hepatology.2014; 12(1): 135.     CrossRef
  • Endoscopic Resection for Early Gastric Cancer beyond Absolute Indication with Emphasis on Controversial Issues
    Yang Won Min, Jun Haeng Lee
    Journal of Gastric Cancer.2014; 14(1): 7.     CrossRef
  • Evaluation of transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent for demonstrating small gastric subepithelial masses
    Zhijun Liu, Jintao Guo, Siyu Sun, Weidong Ren, Shaoshan Tang, Limei Xie, Liping Huang
    Abdominal Imaging.2014; 39(2): 424.     CrossRef
  • Implementation of gastric cancer screening – The global experience
    Mārcis Leja, Weicheng You, M. Constanza Camargo, Hiroshi Saito
    Best Practice & Research Clinical Gastroenterology.2014; 28(6): 1093.     CrossRef
  • Endoscopic Gastric Cancer Screening and Surveillance in High-Risk Groups
    Il Ju Choi
    Clinical Endoscopy.2014; 47(6): 497.     CrossRef
  • Barriers to Cancer Screening among Medical Aid Program Recipients in the Republic of Korea: A Qualitative Study
    Yoon Young Lee, Jae Kwan Jun, Mina Suh, BoYoung Park, Yeol Kim, Kui Son Choi
    Asian Pacific Journal of Cancer Prevention.2014; 15(2): 589.     CrossRef
  • D1 versus D2 lymphadenectomy for gastric cancer
    Benjamin Schmidt, Sam S. Yoon
    Journal of Surgical Oncology.2013; 107(3): 259.     CrossRef
  • Staging of intestinal‐ and diffuse‐type gastric cancers with theOLGAandOLGIMstaging systems
    S.‐J. Cho, I. J. Choi, M.‐C. Kook, B.‐H. Nam, C. G. Kim, J. Y. Lee, K. W. Ryu, Y.‐W. Kim
    Alimentary Pharmacology & Therapeutics.2013; 38(10): 1292.     CrossRef
  • Outcomes and Efficiency of National Gastric Cancer Screening Program in Korea
    Sang Wook Lee, Beom Jin Kim, Jung Duck Park, Jae Gyu Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2013; 13(2): 95.     CrossRef
  • Cost-effectiveness Outcomes of the National Gastric Cancer Screening Program in South Korea
    Eun Cho, Moon Hae Kang, Kui Son Choi, MiNa Suh, Jae Kwan Jun, Eun-Cheol Park
    Asian Pacific Journal of Cancer Prevention.2013; 14(4): 2533.     CrossRef
  • Current evidence of effects ofHelicobacter pylorieradication on prevention of gastric cancer
    Il Ju Choi
    The Korean Journal of Internal Medicine.2013; 28(5): 525.     CrossRef
  • Discrimination of gastric cancer from normal by serum RNA based on surface‐enhanced Raman spectroscopy (SERS) and multivariate analysis
    Yanping Chen, Gang Chen, Xiongwei Zheng, Cheng He, Shangyuan Feng, Yan Chen, Xiaoqian Lin, Rong Chen, Haisan Zeng
    Medical Physics.2012; 39(9): 5664.     CrossRef
  • Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2011
    Boyoung Park, Kui Son Choi, Yoon Young Lee, Jae Kwan Jun, Hong Gwan Seo
    Cancer Research and Treatment.2012; 44(2): 113.     CrossRef
  • U.S. Geriatricians and Gastric Cancer Screening in Elderly Korean‐American Men: Differences from Korean Geriatricians
    Chang Won Won, Hwan‐Sik Hwang
    Journal of the American Geriatrics Society.2012; 60(5): 996.     CrossRef
  • Effectiveness of Interventions to Increase the Participation Rate of Gastric Cancer Screening in the Republic of Korea: a Pilot study
    Myung-Ha Lee, Yoon-Young Lee, Da-Won Jung, Bo-Young Park, E-Hwa Yun, Hoo-Yeon Lee, Jae-Kwan Jun, Kui-Son Choi
    Asian Pacific Journal of Cancer Prevention.2012; 13(3): 861.     CrossRef
  • Endoscopist Specialty Is Associated with High-Quality Endoscopy in Korea
    Jae Myung Cha, Dong Soo Han, Hang Lack Lee, Young Ho Kim, Il-Kwun Chung, Hyun Soo Kim, Jeong Seop Moon, Yu Kyung Cho
    Yonsei Medical Journal.2012; 53(2): 310.     CrossRef
  • Cancer Screening Status in Korea, 2011: Results from the Korean National Cancer Screening Survey
    Bo-Young Park, Kui-Son Choi, Yoon-Young Lee, Jae-Kwan Jun, Hong-Gwan Seo
    Asian Pacific Journal of Cancer Prevention.2012; 13(4): 1187.     CrossRef
  • Current Management and Future Strategies of Gastric Cancer
    Joong Ho Lee, Kyung Min Kim, Jae-Ho Cheong, Sung Hoon Noh
    Yonsei Medical Journal.2012; 53(2): 248.     CrossRef
  • Intestinal Metaplasia and the Risk of Gastric Cancer in an Immigrant Asian Population
    Amir Abadir, Catherine Streutker, Christine Brezden-Masley, Andrea Grin, Young-In Kim
    Clinical Medicine Insights: Gastroenterology.2012; 5: CGast.S10070.     CrossRef
  • Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2010
    Eun-Ha Lee, Hoo-Yeon Lee, Kui Son Choi, Jae Kwan Jun, Eun-Cheol Park, Jin Soo Lee
    Cancer Research and Treatment.2011; 43(3): 141.     CrossRef
  • 12,564 View
  • 88 Download
  • 74 Crossref
Close layer
Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
Su Jin Lee, Silvia Park, Hee Kyung Ahn, Jun Ho Yi, Eun Yoon Cho, Jong Mu Sun, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im
Cancer Res Treat. 2011;43(2):89-95.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.89
AbstractAbstract PDFPubReaderePub
PURPOSE
The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis.
MATERIALS AND METHODS
Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases.
RESULTS
The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077).
CONCLUSION
Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'

Citations

Citations to this article as recorded by  
  • Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis
    Nour Arakil, Shahid Akhtar Akhund, Basant Elaasser, Khalid S. Mohammad
    Biomedicines.2024; 12(5): 1075.     CrossRef
  • Germacrone alleviates breast cancer‐associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF‐κB signaling pathways
    Zhengjun Lin, Yaocheng Yang, Tang Liu, Ziyi Wu, Xianghong Zhang, Jing Yang
    Phytotherapy Research.2024; 38(6): 2860.     CrossRef
  • Acro metastasis: A rare presentation in a common cancer
    Ali Ghanei-Shahmirzadi, Nasrin Namdari, Maral Mokhtari, Pooya Iranpour
    Current Problems in Cancer: Case Reports.2024; 14: 100292.     CrossRef
  • Concise review: breast cancer stems cells and their role in metastases
    Mohammad Kamalabadi Farahani, Mohammad Farjadmehr, Amir Atashi, Alireza Momeni, Mahin Behzadifard
    Annals of Medicine & Surgery.2024; 86(9): 5266.     CrossRef
  • Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion
    Dominique Leblanc, Guy Cantin, Alexandra Desnoyers, Jean Dufresne, Giuseppina Laura Masucci, Valérie Panet-Raymond, Éric Poirier, Sara Soldera, Isabelle Gingras
    Current Oncology.2023; 30(2): 1416.     CrossRef
  • Surgery in the Setting of Metastatic Breast Cancer
    Jennifer K. Plichta, Mahsa Taskindoust, Rachel A. Greenup
    Current Breast Cancer Reports.2023; 15(1): 37.     CrossRef
  • Team Approach: Management of Pathologic Fractures
    Aws Hammad, Osman Ahmed, Philip P. Connell, Daniel Olson, Tessa Balach
    JBJS Reviews.2023;[Epub]     CrossRef
  • Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study
    Gianluca Bottoni, Francesco Fiz, Matteo Puntoni, Federica Matteucci, Manuela Monti, Andrea DeCensi, Oriana Nanni, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gianmauro Sacchetti, Pierpaolo Trimboli, Giorgio Treglia, Nadia Harbeck, Simona Sola, Alessan
    European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(8): 2477.     CrossRef
  • Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
    Alexandre Prieur, Andrew Harper, Momtafin Khan, Bérengère Vire, Dominique Joubert, Léa Payen, Karen Kopciuk
    BMC Cancer.2023;[Epub]     CrossRef
  • SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches
    Qiuyao Wu, Pu Tian, Dasa He, Zhenchang Jia, Yunfei He, Wenqian Luo, Xianzhe Lv, Yuan Wang, Peiyuan Zhang, Yajun Liang, Wenjin Zhao, Jun Qin, Peng Su, Yi-Zhou Jiang, Zhi-Ming Shao, Qifeng Yang, Guohong Hu
    Cell Research.2023; 33(6): 464.     CrossRef
  • Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
    Mónica Cejuela, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, Javier Salvador Bofill
    International Journal of Molecular Sciences.2023; 24(10): 8488.     CrossRef
  • Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer
    Kang Yao, Zhu Xiaojun, Zhao Tingxiao, Liao Shiyao, Ji Lichen, Zhang Wei, Li Yanlei, Tian Jinlong, Ding Xiaoyan, Zhang Jun, Bi Qing, Lv Jun
    BMC Cancer.2023;[Epub]     CrossRef
  • Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept
    Francesco Fiz, Gianluca Bottoni, Giorgio Treglia, Pierpaolo Trimboli, Arnoldo Piccardo
    Journal of Clinical Medicine.2022; 11(13): 3589.     CrossRef
  • Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis
    Cheng-cheng Yu, Yi-nan Wu, Kai-min Hu, Su-zhan Zhang, Ali Imran
    BioMed Research International.2022; 2022: 1.     CrossRef
  • Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis
    Wucheng Wen, Pengbo Guo, Hui Yi Xue, Ho Lun Wong
    International Journal of Pharmaceutics.2022; 625: 122092.     CrossRef
  • Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer
    Lina Marie, Dina Braik, Nayef Abdel-Razeq, Hala Abu-Fares, Ahmad Al-Thunaibat, Hikmat Abdel-Razeq
    Cancer Management and Research.2022; Volume 14: 2519.     CrossRef
  • Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
    Lulian Pang, Chen Gan, Jian Xu, Yingxue Jia, Jiaying Chai, Runze Huang, Anlong Li, Han Ge, Sheng Yu, Huaidong Cheng
    Cancers.2022; 14(23): 5727.     CrossRef
  • Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?
    E. Pons-Tostivint, E. Alouani, Y. Kirova, F. Dalenc, C. Vaysse
    Critical Reviews in Oncology/Hematology.2021; 157: 103146.     CrossRef
  • Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study
    Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim
    European Journal of Cancer.2021; 144: 341.     CrossRef
  • Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone
    Shuzhong Liu, An Song, Yunxiao Wu, Siyuan Yao, Muchuan Wang, Tong Niu, Chengao Gao, Ziquan Li, Xi Zhou, Zhen Huo, Bo Yang, Yong Liu, Yipeng Wang
    Translational Oncology.2021; 14(2): 100993.     CrossRef
  • Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis
    Chiara Spadazzi, Laura Mercatali, Mark Esposito, Yong Wei, Chiara Liverani, Alessandro De Vita, Giacomo Miserocchi, Elisa Carretta, Michele Zanoni, Claudia Cocchi, Alberto Bongiovanni, Federica Recine, Yibin Kang, Toni Ibrahim
    Bone.2021; 144: 115775.     CrossRef
  • Diagnosis and referral of adults with suspected bony metastases
    Samantha Downie, Elizabeth Bryden, Fergus Perks, A Hamish RW Simpson
    BMJ.2021; : n98.     CrossRef
  • Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
    Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos
    Cancers.2021; 13(6): 1458.     CrossRef
  • Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT
    Gianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, Giacomo Siri, Federica Matteucci, Andrea Rocca, Oriana Nanni, Manuela Monti, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gian Mauro Sacchetti, Chiara Saggia, Valentina Rossi, Nadia Harbeck, Rachel Wue
    European Journal of Radiology.2021; 141: 109821.     CrossRef
  • Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
    Daniel Reinhorn, Raz Mutai, Rinat Yerushalmi, Assaf Moore, Eitan Amir, Hadar Goldvaser
    The Breast.2021; 58: 173.     CrossRef
  • Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer
    Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi
    Nature Communications.2021;[Epub]     CrossRef
  • Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?
    Adam S. Komorowski, Ellen Warner, Helen J. MacKay, Arjun Sahgal, Kathleen I. Pritchard, Katarzyna J. Jerzak
    Clinical Breast Cancer.2020; 20(1): e54.     CrossRef
  • Radiation therapy for bone-only metastases in breast cancer patients: A GOCO survey of current clinical practice
    Marta Bonet, Virginia García, Núria Farré, Manel Algara, Blanca Farrús, Jaume Fernandez, Victoria Reyes, Arancha Eraso, Ana Álvarez, Maria José Cambra, Agustí Pedro, Jordi Vayreda, Claire Lemansky, Françoise Izar, Meritxell Arenas
    Reports of Practical Oncology & Radiotherapy.2020; 25(1): 113.     CrossRef
  • MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9
    Xinxin Zhang, Xiying Yu, Zhenguo Zhao, Zhennan Yuan, Peiqing Ma, Zhibin Ye, Liping Guo, Songfeng Xu, Libin Xu, Ting Liu, Huanmei Liu, Shengji Yu
    Bone.2020; 130: 115139.     CrossRef
  • Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival
    Najla Itani, Nicole Grogan, Sarah Mott, Sneha Phadke
    Clinical Breast Cancer.2020; 20(3): 209.     CrossRef
  • Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
    Cynthia Huang Bartlett, Jack Mardekian, Matthew James Cotter, Xin Huang, Zhe Zhang, Christina M. Parrinello, Ariel Bulua Bourla, Apar Kishor Ganti
    PLOS ONE.2020; 15(4): e0227256.     CrossRef
  • International Framework for Red Flags for Potential Serious Spinal Pathologies
    Laura M. Finucane, Aron Downie, Christopher Mercer, Susan M. Greenhalgh, William G. Boissonnault, Annelies L. Pool-Goudzwaard, Jason M. Beneciuk, Rachel L. Leech, James Selfe
    Journal of Orthopaedic & Sports Physical Therapy.2020; 50(7): 350.     CrossRef
  • Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
    Liang Jin, Kai Chen, Cui Tan, Jianbin Li, Jiayue Luo, Yaping Yang, Yudong Li, Shunying Li, Liling Zhu, Yue Hu, Fengtao Liu, Qiuting You, Min Peng, Zefei Jiang, Qiang Liu
    The Oncologist.2020; 25(8): e1170.     CrossRef
  • Imaging diagnosis of metastatic breast cancer
    Filippo Pesapane, Kate Downey, Anna Rotili, Enrico Cassano, Dow-Mu Koh
    Insights into Imaging.2020;[Epub]     CrossRef
  • Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells
    Yung-Chieh Chang, Chun Hei Antonio Cheung, Yao-Lung Kuo
    Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
  • Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
    Richard S. Finn, Massimo Cristofanilli, Johannes Ettl, Karen A. Gelmon, Marco Colleoni, Carla Giorgetti, Eric Gauthier, Yuan Liu, Dongrui R. Lu, Zhe Zhang, Cynthia Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Hope S. Rugo
    Breast Cancer Research and Treatment.2020; 184(1): 23.     CrossRef
  • Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons
    Ania Naila Guerrieri, Monica Montesi, Simone Sprio, Roberta Laranga, Laura Mercatali, Anna Tampieri, Davide Maria Donati, Enrico Lucarelli
    Frontiers in Bioengineering and Biotechnology.2020;[Epub]     CrossRef
  • The influence of breast cancer subtype on survival after palliative radiation for osseous metastases
    Mohamed K. Abdelhakiem, Candice Johnstone, Carmen Bergom, Adam Currey, Jared R. Robbins
    Cancer Medicine.2020; 9(23): 8979.     CrossRef
  • Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics
    Jin-Xiao Ren, Yue Gong, Hong Ling, Xin Hu, Zhi-Ming Shao
    Breast Cancer Research and Treatment.2019; 173(1): 225.     CrossRef
  • Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study
    Kang Wang, Yang Shi, Zhu-Yue Li, Ye-Lei Xiao, Jie Li, Xiang Zhang, Hong-Yuan Li
    European Journal of Surgical Oncology.2019; 45(8): 1364.     CrossRef
  • The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis
    Ricardo Romero-Moreno, Kimberly J. Curtis, Thomas R. Coughlin, Maria Cristina Miranda-Vergara, Shourik Dutta, Aishwarya Natarajan, Beth A. Facchine, Kristen M. Jackson, Lukas Nystrom, Jun Li, William Kaliney, Glen L. Niebur, Laurie E. Littlepage
    Nature Communications.2019;[Epub]     CrossRef
  • Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study
    Guenther G. Steger, Adriana Dominguez, Natalia Dobrovolskaya, Francesco Giotta, Nicole Tubiana-Mathieu, Martin Pecherstorfer, Antonio Ardizzoia, Maria Blasinska-Morawiec, Enrique Espinosa, Gustavo Villanova
    Clinical Breast Cancer.2018; 18(1): e41.     CrossRef
  • Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
    Judith A. Malmgren, Musa Mayer, Mary K. Atwood, Henry G. Kaplan
    Breast Cancer Research and Treatment.2018; 167(2): 579.     CrossRef
  • Breast cancer bone metastases: pathogenesis and therapeutic targets
    Naomi Brook, Emily Brook, Arun Dharmarajan, Crispin R. Dass, Arlene Chan
    The International Journal of Biochemistry & Cell Biology.2018; 96: 63.     CrossRef
  • Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data
    Hongwei Zhang, Wei Zhu, Ewelina Biskup, Weige Yang, Ziang Yang, Hong Wang, Xiaochun Qiu, Chengjiao Zhang, Guangxia Hu, Guangfu Hu
    Journal of Bone Oncology.2018; 11: 38.     CrossRef
  • Breast osteoblast-like cells: a new biomarker for the management of breast cancer
    Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Orazio Schillaci, Elena Bonanno
    British Journal of Cancer.2018; 119(9): 1129.     CrossRef
  • Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita
    Breast Cancer.2017; 24(3): 473.     CrossRef
  • Pattern of metastatic spread and subcategories of breast cancer
    Catharina Bartmann, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Joachim Diessner
    Archives of Gynecology and Obstetrics.2017; 295(1): 211.     CrossRef
  • Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid
    Claudia Omarini, Maria E. Filieri, Roberta Depenni, Giulia Grizzi, Stefano Cascinu, Federico Piacentini
    The Breast Journal.2017; 23(5): 610.     CrossRef
  • The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone
    Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca‐Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean‐Luc Coll, Isabelle Treilleux, Véronique Maguer‐Satta, Véroniqu
    The Journal of Pathology.2017; 242(1): 73.     CrossRef
  • Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis
    I Bado, Z Gugala, S A W Fuqua, X H-F Zhang
    Oncogene.2017; 36(32): 4527.     CrossRef
  • Which red flags aid the early detection of metastatic bone disease in back pain?
    Laura Finucane, Susan Greenhalgh, James Selfe
    Physiotherapy Practice and Research.2017; 38(2): 73.     CrossRef
  • Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis
    Soyeon Park, Joon-Kee Yoon, Su Jin Lee, Seok Yun Kang, Hyunee Yim, Young-Sil An
    Medicine.2017; 96(50): e8985.     CrossRef
  • Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
    Shinji Ohno
    Clinical Breast Cancer.2016; 16(4): 238.     CrossRef
  • Quality of life and symptom burden in patients with metastatic breast cancer
    Christine Ecclestone, Ronald Chow, Natalie Pulenzas, Liying Zhang, Angela Leahey, Julia Hamer, Carlo DeAngelis, Gillian Bedard, Rachel McDonald, Anchal Bhatia, Janet Ellis, Eileen Rakovitch, Sherlyn Vuong, Edward Chow, Sunil Verma
    Supportive Care in Cancer.2016; 24(9): 4035.     CrossRef
  • Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
    Joachim Diessner, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Catharina Bartmann
    BMC Cancer.2016;[Epub]     CrossRef
  • Prolactin receptor in breast cancer: marker for metastatic risk
    Carrie S Shemanko
    Journal of Molecular Endocrinology.2016; 57(4): R153.     CrossRef
  • Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers
    Megumi Kai, Takahiro Kogawa, Diane D. Liu, Tamer M. Fouad, Kazuharu Kai, Naoki Niikura, Limin Hsu, Jie S. Willey, Richard L. Theriault, Vicente Valero, Naoto T. Ueno
    Clinical Breast Cancer.2015; 15(1): 37.     CrossRef
  • Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer
    Iain R. Macpherson, Caroline Bray, Carol Hopkins, Rosemary A. Hannon, Liz-Anne Lewsley, Diana M. Ritchie, Peter Canney
    Clinical Breast Cancer.2015; 15(2): 117.     CrossRef
  • Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?
    D.K. Woolf, A.R. Padhani, A. Makris
    Annals of Oncology.2015; 26(6): 1048.     CrossRef
  • Survival time according to the year of recurrence and subtype in recurrent breast cancer
    Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Ohsako, Yasuo Toyozumi, Nobuyuki Arima, Reiki Nishimura
    The Breast.2015; 24(5): 588.     CrossRef
  • Cases of Bone-only Metastasis in Recurrent Breast Cancer
    Yoko MAEKAWA, Shintaro TAKAO, Koichi HIROKAGA, Mayuko MIKI, Sachiko YOSHIDA
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2014; 75(6): 1484.     CrossRef
  • Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
    June Koo Lee, Seock-Ah Im, Daewon Lee, Ji-Yeon Kim, Yoojoo Lim, Eunyoung Lee, Hyeong-Gon Moon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh
    Journal of Breast Cancer.2013; 16(1): 66.     CrossRef
  • Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
    I. Kuchuk, B. Hutton, P. Moretto, T. Ng, C.L. Addison, M. Clemons
    Journal of Bone Oncology.2013; 2(4): 137.     CrossRef
  • Zooming in on the schedule of bone-modifying drugs
    Miguel Martin, Sara López-Tarruella
    The Lancet Oncology.2013; 14(7): 575.     CrossRef
  • Bone metastases: assessment, management and treatment options
    Carole Farrell
    British Journal of Nursing.2013; 22(Sup7): S4.     CrossRef
  • Limites de la scintigraphie osseuse dans le suivi des métastases osseuses du carcinome mammaire : étude du centre tunisien
    K. Chatti, A. Harrabi, I. Chabchoub, T. Kamoun, R. Sfar, M. Nouira, M.B. Fredj, N. Ayachi, S.B. Ahmed, H. Essabbah
    Médecine Nucléaire.2012; 36(10): 574.     CrossRef
  • 14,489 View
  • 141 Download
  • 67 Crossref
Close layer
A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
Soon Il Lee, Se Hoon Park, Do Hyoung Lim, Keon Woo Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2011;43(2):96-101.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.96
AbstractAbstract PDFPubReaderePub
PURPOSE
Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or irinotecan, has demonstrated efficacy and tolerability in treatment of advanced colorectal cancer (ACC).
MATERIALS AND METHODS
Between January 2006 and December 2007, a total of 478 ACC patients were treated with combination chemotherapy in first-line settings. Combination therapies included: 5-fluorouracil, folinic acid plus oxaliplatin (FOLFOX, n=172), 5-fluorouracil, folinic acid plus irinotecan (FOLFIRI, n=95), capecitabine plus oxaliplatin (XELOX, n=155), and capecitabine plus irinotecan (XELIRI, n=56). FOLFOX and FOLFIRI were repeated every 2 weeks, whereas XELOX and XELIRI were repeated every 3 weeks until occurrence of disease progression or unacceptable toxicity, or until a patient chose to discontinue treatment.
RESULTS
The median age was 58 years (range, 19 to 84 years) and the median chemotherapy durations for FOLFOX, FOLFIRI, XELOX, and XELIRI were 4.9, 4.5, 5.7, and 5.4 months, respectively. Combination chemotherapy regimens were generally well tolerated. The estimated median progression-free-survival (PFS) for all patients was 6.8 months (95% confidence interval, 6.3 to 7.3 months). No statistically significant difference in PFS was found among regimens used as first-line chemotherapy. Sixty percent (n=290) of patients received second or further lines of therapy after failure.
CONCLUSION
Fluoropyrimidine-based combination chemotherapy regimens appear to be equally active and tolerable as first-line therapy for ACC.

Citations

Citations to this article as recorded by  
  • Nineteen-year, real-world experience of first-line combination chemotherapy in patients with metastatic colorectal cancer: a propensity score analysis from southern Thailand
    Jirapat Wonglhow, Chirawadee Sathitruangsak, Arunee Dechaphunkul, Patrapim Sunpaweravong
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
    Si-Qi Dong, Tong-Min Wang, Jiang-Bo Zhang, Yong-Qiao He, Wen-Qiong Xue, Zi-Yi Wu, Da-Wei Yang, Lian-Jing Cao, Jing-Wen Huang, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Wei-Hua Jia
    Cancer Research and Treatment.2021; 53(3): 724.     CrossRef
  • 10,356 View
  • 75 Download
  • 2 Crossref
Close layer
Surgical Outcomes of Hemorrhagic Metastatic Brain Tumors
Heon Yoo, Eugene Jung, Ho Shin Gwak, Sang Hoon Shin, Seung Hoon Lee
Cancer Res Treat. 2011;43(2):102-107.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.102
AbstractAbstract PDFPubReaderePub
PURPOSE
Hemorrhagic metastatic brain tumors are not rare, but little is known about the surgical outcome following treatment. We conducted this study to determine the result of the surgical outcome of hemorrhagic metastatic brain tumors.
MATERIALS AND METHODS
From July 2001 to December 2008, 21 patients underwent surgery for hemorrhagic metastatic brain tumors at our institution. 15 patients had lung cancer, 3 had hepatocellular carcinoma, and the rest had rectal cancer, renal cell carcinoma, and sarcoma. 20 patients had macroscopic hemorrhage in the tumors, and one patient had intracerebral hemorrhage surrounding the tumor. A retrospective clinical review was conducted focusing on the patterns of presenting symptoms and signs, as well as local recurrence following surgery.
RESULTS
Among 21 hemorrhagic brain metastases, local recurrence developed in two patients. The 12 month progression free survival rate was 86.1%. Mean time to progression was 20.8 months and median survival time after surgery was 11.7 months.
CONCLUSION
The results of our study showed that hemorrhagic metastatic brain tumors rarely recurred after surgery. Surgery should be considered as a good treatment option for hemorrhagic brain metastasis, especially in cases with increased intracranial pressure or severe neurologic deficits.

Citations

Citations to this article as recorded by  
  • Predictors and surgical outcome of hemorrhagic metastatic brain malignancies
    Laurèl Rauschenbach, Pia Kolbe, Adrian Engel, Yahya Ahmadipour, Marvin Darkwah Oppong, Alejandro N. Santos, Sied Kebir, Celia Dobersalske, Björn Scheffler, Cornelius Deuschl, Philipp Dammann, Karsten H. Wrede, Ulrich Sure, Ramazan Jabbarli
    Journal of Neuro-Oncology.2024; 169(1): 165.     CrossRef
  • Should we be afraid of radiotherapy for hemorrhagic brain metastases? A narrative review
    Aleksandra Łupicka, Weronika Kowalczyk, Bartosz Cyman, Mateusz Spałek
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Hemorrhagic brain metastasis from small-cell carcinoma of the urinary bladder
    Kazuhide Maeshima, Takahiro Sasaki, Toshikazu Yamoto, Junya Fukai, Hiroki Nishibayashi, Naoyuki Nakao
    Surgical Neurology International.2022; 13: 20.     CrossRef
  • Hemorrhage in brain tumor – An unresolved issue
    Robert P. Ostrowski, Zhaohui He, Emanuela B. Pucko, Ewa Matyja
    Brain Hemorrhages.2022; 3(2): 98.     CrossRef
  • Cardiac Angiosarcomas
    Andrew J. Bishop, Jing Zheng, Aparna Subramaniam, Amol J. Ghia, Chenyang Wang, Susan L. McGovern, Shreyaskumar Patel, B. Ashleigh Guadagnolo, Devarati Mitra, Ahsan Farooqi, Michael J. Reardon, Betty Kim, Nandita Guha-Thakurta, Jing Li, Vinod Ravi
    American Journal of Clinical Oncology.2022; 45(6): 258.     CrossRef
  • Correlation Analysis between Retention of Gd-DTPA in the Cystic Area of Brain Metastasis and MRI Signs
    Jili Wang, Shanshan Qu, Qinyan Xu, Zhaofeng Jin, Tian Li, Shuxian Zhang, Xihe Sun, Qingbin Cui
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis
    Muhammad Khan, Tao Zheng, Zhihong Zhao, Sumbal Arooj, Guixiang Liao
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Management of patients suffering from hemorrhagic intracranial metastases: Propositions to help the neurosurgeon in emergency situations based on a literature review
    S. Boissonneau, T. Graillon, A. Rolland, C. Botella, J. Pallud, H. Dufour
    Neurochirurgie.2021; 67(4): 369.     CrossRef
  • 3D Spatial Distribution of Nanoparticles in Mice Brain Metastases by X-ray Phase-Contrast Tomography
    Elena Longo, Lucie Sancey, Alessia Cedola, Emmanuel L. Barbier, Alberto Bravin, Francesco Brun, Inna Bukreeva, Michela Fratini, Lorenzo Massimi, Imke Greving, Geraldine Le Duc, Olivier Tillement, Ombeline De La Rochefoucauld, Philippe Zeitoun
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Critical cerebellar hemorrhage due to pilocytic astrocytoma in a child: A case report
    Akihiko Teshigawara, Toshikazu Kimura, Shunsuke Ichi
    Surgical Neurology International.2021; 12: 448.     CrossRef
  • Preoperative Metastatic Brain Tumor-Associated Intracerebral Hemorrhage Is Associated With Dismal Prognosis
    Motaz Hamed, Niklas Schäfer, Christian Bode, Valeri Borger, Anna-Laura Potthoff, Lars Eichhorn, Frank A. Giordano, Erdem Güresir, Muriel Heimann, Yon-Dschun Ko, Jennifer Landsberg, Felix Lehmann, Alexander Radbruch, Elisa Scharnböck, Christina Schaub, Kat
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker
    Grant M. Fischer, Fernando C. L. Carapeto, Aron Y. Joon, Lauren E. Haydu, Huiqin Chen, Fuchenchu Wang, John S. Van Arnam, Jennifer L. McQuade, Khalida Wani, John M. Kirkwood, John F. Thompson, Michael T. Tetzlaff, Alexander J. Lazar, Hussein A. Tawbi, Jef
    Cancer Medicine.2020; 9(22): 8650.     CrossRef
  • Over-expression of S100B protein as a serum marker of brain metastasis in non-small cell lung cancer and its prognostic value
    Lijuan Chen, Xiufeng Hu, Huijuan Wu, Yongxu Jia, Jie Liu, Xiaoqian Mu, Hongbo Wu, Yanqiu Zhao
    Pathology - Research and Practice.2019; 215(3): 427.     CrossRef
  • La radiothérapie en conditions stéréotaxiques des métastases cérébrales en situation complexe
    G. Noel, A. Keller, D. Antoni
    Cancer/Radiothérapie.2019; 23(6-7): 708.     CrossRef
  • Multiple massive intratumoral hemorrhages of metastatic brain melanoma after ventriculoperitoneal shunt
    Tsung-Hsi Yang, Jung-Tung Liu, Fook-How Chan
    Formosan Journal of Surgery.2019; 52(3): 99.     CrossRef
  • Two Cases of Metastatic Malignant Melanoma
    Keijiro Hara, Kazuhiro Hirano, Yukari Ogawa, Keita Kinoshita, Satoshi Hirai, Hiroki Takai, Nobuhisa Matsushita, Hiroyuki Toi, Hirotake Nishimura, Ryo Tanaka, Shunji Matsubara, Masaaki Uno
    Japanese Journal of Neurosurgery.2018; 27(5): 393.     CrossRef
  • Stereotactic radiosurgery for brain metastases from malignant melanoma and the impact of hemorrhagic metastases
    Kristine Bauer-Nilsen, Daniel M. Trifiletti, Ajay Chatrath, Henry Ruiz-Garcia, Eduardo Marchan, Jennifer Peterson, Byron C. May, Jason P. Sheehan
    Journal of Neuro-Oncology.2018; 140(1): 83.     CrossRef
  • Posterior Fossa Metastasis–Associated Obstructive Hydrocephalus in Adult Patients: Literature Review and Practical Considerations from the Neuro-Oncology Club of the French Society of Neurosurgery
    Alexandre Roux, Céline Botella, Megan Still, Marc Zanello, Frédéric Dhermain, Philippe Metellus, Johan Pallud
    World Neurosurgery.2018; 117: 271.     CrossRef
  • Cerebellar hemorrhage due to dural arteriovenous fistula mimicking a hemorrhagic metastatic brain tumor: a case report
    Yoichi Yoshida, Yoshinori Higuchi, Ryota Nomura, Shiro Ikegami, Toshimasa Shin, Ayaka Hara, Taiki Setoguchi, Eiichi Kobayashi, Kazuhiro Nomoto, Yasuo Iwadate
    Nosotchu.2018; 40(6): 427.     CrossRef
  • Risk of Cerebrovascular Events in 178 962 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age
    Chloe J. Bright, Mike M. Hawkins, Joyeeta Guha, Katherine E. Henson, David L. Winter, Julie S. Kelly, Richard G. Feltbower, Marlous Hall, David J. Cutter, Angela B. Edgar, Clare Frobisher, Raoul C. Reulen
    Circulation.2017; 135(13): 1194.     CrossRef
  • Hemorrhage of brain metastasis is a poor prognostic factor in hepatocellular carcinoma patients
    Yan Lin, Shi-Ting Huang, Yan-Ming Jiang, Xin-Bin Pan
    Oncotarget.2017; 8(54): 93245.     CrossRef
  • Pointing to the Diagnosis: Hemorrhagic Brain Metastasis
    Yu-Hsiang Juan, Huei-Fang Hsuan, Yun-Chung Cheung, Shu-Hang Ng, Koon-Kwan Ng, Chin-Wei Yu, Yu-Ying Cheng, Yu-Ching Lin
    The American Journal of Medicine.2016; 129(12): 1268.     CrossRef
  • Anesthetic Management of Supratentorial Tumors
    Abirami Kumaresan, Ekkehard Kasper, Ruma Bose
    International Anesthesiology Clinics.2015; 53(1): 74.     CrossRef
  • Brain Metastasis From Papillary Thyroid Carcinoma in a Seventy-Three-Year-Old Man
    Babak Alijani, Mohammad Reza Emamhadi, Shahrokh Yousefzadeh Chabok, Hamid Behzadnia, Siavash Dehghani
    Archives of Neuroscience.2015;[Epub]     CrossRef
  • Post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma
    Kyung Su Kim, Kyubo Kim, Eui Kyu Chie, Yoon Jun Kim, Jung Hwan Yoon, Hyo-Suk Lee, Sung W. Ha
    Radiation Oncology Journal.2015; 33(1): 36.     CrossRef
  • Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
    Benjamin Besse, Sylvestre Le Moulec, Julien Mazières, Hélène Senellart, Fabrice Barlesi, Christos Chouaid, Eric Dansin, Henri Bérard, Lionel Falchero, Radj Gervais, Gilles Robinet, Anne-Marie Ruppert, Roland Schott, Hervé Léna, Christelle Clément-Duchêne,
    Clinical Cancer Research.2015; 21(8): 1896.     CrossRef
  • 16,532 View
  • 137 Download
  • 26 Crossref
Close layer
An Association Study of Polymorphisms in JAK3 Gene with Lung Cancer in the Korean Population
Wonbeak Yoo, Hae-Yun Jung, Seungjoon Lim, Jae Sook Sung, Kyong Hwa Park, Jeong Seon Ryu, Sang Won Shin, Jun Suk Kim, Jae Hong Seo, Yeul Hong Kim
Cancer Res Treat. 2011;43(2):108-116.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.108
AbstractAbstract PDFPubReaderePub
PURPOSE
The genetic alteration of the janus kinases (JAKs), non-receptor tyrosine kinase, is related to the development of human cancers. However, little is known about how the sequence variation of JAK3 contributes to the development of lung cancer. This study investigated whether polymorphisms at the promoter region of the JAK3 gene are associated with the risk of lung cancer in the Korean population.
MATERIALS AND METHODS
A total of 819 subjects, including 409 lung cancer patients and 410 healthy controls were recruited. The SNaPshot assay and polymerase chain reaction-restriction fragment length polymorphism analysis were used, and logistic regression analyses were performed to characterize the association between polymorphisms of JAK3 and lung cancer risk.
RESULTS
Three polymorphisms (-672 G>A, +64 A>G and +227 G>A) of JAK3 were analyzed for large-scale genotyping (n=819). Statistical analyses revealed that polymorphisms and haplotypes in the JAK3 gene were not significantly associated with lung cancer.
CONCLUSION
JAK3 gene was not significantly associated with the risk of lung cancer in the Korean population.

Citations

Citations to this article as recorded by  
  • Association Analysis of Polymorphic Gene Variants in the JAK/STAT Signaling Pathway with Aging and Longevity
    V. V. Erdman, T. R. Nasibullin, I. A. Tuktarova, R. Sh. Somova, O. E. Mustafina
    Russian Journal of Genetics.2019; 55(6): 728.     CrossRef
  • 10,598 View
  • 55 Download
  • 1 Crossref
Close layer
Predictive Value of In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Advanced Gastric Cancer Patients Who Received Oral 5-Fluorouracil after Curative Resection
Ji Hyun Lee, Min-Chan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Sung-Hyun Kim, Kyung A Kwon, Suee Lee, Jin Sook Jeong, Seok-Reyol Choi, Hyo-Jin Kim
Cancer Res Treat. 2011;43(2):117-123.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.117
AbstractAbstract PDFPubReaderePub
PURPOSE
To assess the usefulness of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) results in advanced gastric cancer patients receiving adjuvant chemotherapy.
MATERIALS AND METHODS
Sixty-two patients underwent curative surgical resection between January, 2006 and December, 2008. Their highly purified surgical specimens were evaluated by ATP-CRAs. Of the 62, 49 had successful assay results and they received either oral 5-fluorouracil or other chemotherapies. We retrospectively analyzed data for 24 patients who were treated with oral 5-fluorouracil and whose assays were successful.
RESULTS
The median observation time was 24.6 months (range, 10.1 to 40.9 months). The median treatment time was 11.2 months (range, 1.2 to 17.7 months). The median age was 66 years (range, 30 to 81 years). Patients were grouped into sensitive- and resistant-groups according to adenosine triphosphate-based chemotherapy response results for fluorouracil. The sensitive-group showed a significantly longer time to relapse (not reached in the sensitive-group vs. 24.8 months in the resistant-group, p=0.043) and longer overall survival compared to the resistant-group (not reached in the sensitive-group vs. 35.7 months in the resistant-group, p=0.16, statistically insignificant).
CONCLUSION
Patients who receive curative surgical resection significantly benefit from sensitive adjuvant chemotherapy according to ATP-CRA results for time to relapse.

Citations

Citations to this article as recorded by  
  • In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
    Hye Youn Kwon, Im-kyung Kim, Jeonghyun Kang, Seung-Kook Sohn, Kang Young Lee
    Cancer Research and Treatment.2016; 48(3): 970.     CrossRef
  • Clinical correlation between <i>in vitro</i> chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients
    Sang Hun Jung, So Hyun Kim, Jae Hwang Kim
    Korean Journal of Clinical Oncology.2015; 11(2): 51.     CrossRef
  • Purinergic signalling in the gastrointestinal tract and related organs in health and disease
    Geoffrey Burnstock
    Purinergic Signalling.2014; 10(1): 3.     CrossRef
  • Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes
    KOJI HARADA, TARANNUM FERDOUS, YOSHIYA UEYAMA
    International Journal of Oncology.2014; 44(4): 1302.     CrossRef
  • Purinergic signalling and cancer
    Geoffrey Burnstock, Francesco Di Virgilio
    Purinergic Signalling.2013; 9(4): 491.     CrossRef
  • Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines
    KAZUYA UCHIBORI, ATSUSHI KASAMATSU, MASAHIKO SUNAGA, SATOSHI YOKOTA, TOMOYA SAKURADA, ERIKO KOBAYASHI, MASAHARU YOSHIKAWA, KATSUHIRO UZAWA, SHIRO UEDA, HIDEKI TANZAWA, NOBUNORI SATO
    International Journal of Oncology.2012; 40(4): 1005.     CrossRef
  • 11,297 View
  • 46 Download
  • 6 Crossref
Close layer
Up-regulation of the DR5 Expression by Proteasome Inhibitor MG132 Augments TRAIL-Induced Apoptosis in Soft Tissue Sarcoma Cell Lines
Hee-Jeong Cheong, Kyu Sang Lee, In Sook Woo, Jong-Ho Won, Jae Ho Byun
Cancer Res Treat. 2011;43(2):124-130.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.124
AbstractAbstract PDFPubReaderePub
PURPOSE
Current chemotherapeutics for treating locally advanced or metastatic soft tissue sarcomas (STS) are limited. Accordingly, the present in vitro study was conducted to evaluate the effects of treatment of STS cells with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) applied as a single agent or in combination with a proteasome inhibitor, MG132.
MATERIALS AND METHODS
Sensitivity to TRAIL and activity of TRAIL-induced apoptotic pathways were analyzed in four STS cell lines: HTB-82 (rhabdomyosarcoma), HT-1080 (fibrosarcoma), HTB-93 (synovial sarcoma), and HTB-94 (chondrosarcoma). Reduction of the dye dimethylthiazolyl 2,5 diphenyltetrazolium bromide (MTT) was used to evaluate cytotoxic activity; western blots were used to evaluate TRAIL-induced apoptosis.
RESULTS
TRAIL induced apoptosis in HTB-93 cells, but had little effect in HTB-82, HT-1080, or HTB-94 cells. Expression of TRAIL receptor-1 and -2 did not correlate with sensitivity to TRAIL. Co-incubation of cells with TRAIL and a proteasome inhibitor, MG132, augmented the apoptotic effect of TRAIL in both TRAIL-sensitive and TRAIL-resistant cells. This effect was due to up-regulation of TRAIL receptors and members of the pro-apoptotic BCL-2 family by MG132.
CONCLUSION
These data show that combining TRAIL with MG132 enhances apoptosis and overcomes TRAIL resistance. This restoration of TRAIL sensitivity occurs through an increase in the expression of death receptor 5 and of pro-apoptotic BCL-2 family members such as BAX.

Citations

Citations to this article as recorded by  
  • TRAIL-induced apoptosis and proteasomal activity – Mechanisms, signalling and interplay
    Chiara Boccellato, Markus Rehm
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2024; 1871(4): 119688.     CrossRef
  • Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies
    Edoardo Agosti, Marco Zeppieri, Sara Antonietti, Tamara Ius, Marco Maria Fontanella, Pier Paolo Panciani
    Journal of Personalized Medicine.2024; 14(3): 261.     CrossRef
  • Proteasome inhibitors as anticancer agents
    Giorgia Gazzaroli, Andrea Angeli, Arianna Giacomini, Roberto Ronca
    Expert Opinion on Therapeutic Patents.2023; 33(11): 775.     CrossRef
  • Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells
    Eun Byeol Jo, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Hyojun Park, Yoon-La Choi, Doopyo Hong, Sung Joo Kim
    BMC Cancer.2019;[Epub]     CrossRef
  • Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway
    Mengxiong Wang, Mary E. Law, Bradley J. Davis, Elham Yaaghubi, Amanda F. Ghilardi, Renan B. Ferreira, Chi-Wu Chiang, Olga A. Guryanova, Daniel Kopinke, Coy D. Heldermon, Ronald K. Castellano, Brian K. Law
    Cell Death Discovery.2019;[Epub]     CrossRef
  • The combination of TRAIL and MG-132 induces apoptosis in both TRAIL-sensitive and TRAIL-resistant human follicular lymphoma cells
    Jemal Adem, Mine Eray, Jonna Eeva, Ulla Nuutinen, Jukka Pelkonen
    Leukemia Research.2018; 66: 57.     CrossRef
  • Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets
    Elahe Nazeri, Mohammad Gouran Savadkoohi, Keivan Majidzadeh-A, Rezvan Esmaeili
    Critical Reviews in Oncology/Hematology.2018; 131: 102.     CrossRef
  • TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data
    Zakareya Gamie, Konstantinos Kapriniotis, Dimitra Papanikolaou, Emma Haagensen, Ricardo Da Conceicao Ribeiro, Kenneth Dalgarno, Anja Krippner-Heidenreich, Craig Gerrand, Eleftherios Tsiridis, Kenneth Samora Rankin
    Cancer Letters.2017; 409: 66.     CrossRef
  • Activation of TRAIL‐DR5 pathway promotes sensorineural degeneration in the inner ear
    Shyan‐Yuan Kao, Vitor Y.R. Soares, Arthur G. Kristiansen, Konstantina M. Stankovic
    Aging Cell.2016; 15(2): 301.     CrossRef
  • Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas
    Akira Maekawa, Kenichi Kohashi, Masaaki Kuda, Kunio Iura, Takeaki Ishii, Makoto Endo, Tetsuya Nakatsura, Yukihide Iwamoto, Yoshinao Oda
    BMC Cancer.2016;[Epub]     CrossRef
  • The Importance of Being Dead: Cell Death Mechanisms Assessment in Anti-Sarcoma Therapy
    Santiago Rello-Varona, David Herrero-Martín, Laura Lagares-Tena, Roser López-Alemany, Núria Mulet-Margalef, Juan Huertas-Martínez, Silvia Garcia-Monclús, Xavier García del Muro, Cristina Muñoz-Pinedo, Oscar Martínez Tirado
    Frontiers in Oncology.2015;[Epub]     CrossRef
  • Development of a Novel Class of Mitochondrial Ubiquinol–Cytochrome c Reductase Binding Protein (UQCRB) Modulators as Promising Antiangiogenic Leads
    Hye Jin Jung, Misun Cho, Yonghyo Kim, Gyoonhee Han, Ho Jeong Kwon
    Journal of Medicinal Chemistry.2014; 57(19): 7990.     CrossRef
  • Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells
    Hye Jin Jung, Yonghyo Kim, Junghwa Chang, Sang Won Kang, Jeong Hun Kim, Ho Jeong Kwon
    Journal of Molecular Medicine.2013; 91(9): 1117.     CrossRef
  • Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
    Simone Fulda
    Sarcoma.2012; 2012: 1.     CrossRef
  • 11,079 View
  • 71 Download
  • 14 Crossref
Close layer
Case Reports
Benign Metastasizing Leiomyoma with Multiple Lymph Node Metastasis: A Case Report
Gun Yoon, Tae-Joong Kim, Chang-Ohk Sung, Chel Hun Choi, Jeong-Won Lee, Je-Ho Lee, Duk-Soo Bae, Byoung-Gie Kim
Cancer Res Treat. 2011;43(2):131-133.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.131
AbstractAbstract PDFPubReaderePub
This is a case report about benign metastasizing leiomyoma with multiple lymph node metastasis. A 34-year-old woman received an abdominal myomectomy for a suspicious leiomyoma. On the pathology report, atypical leiomyoma was suspected. Due to the suspicion of multiple lymph node metastasis on pelvis computed tomography (CT) 1 year after the operation, she was transferred to the Samsung Medical Center on October, 2009 for further work up. According to original slide review, it was determined to be a benign leiomyoma with a mitotic count <5/10 high-power fields, little cytological atypia and no tumor cell necrosis. Additional immunostaining was done. Multiple lymph node metastasis and a small lung nodule were identified on positron emission tomogarphy-CT and chest CT. Extensive debulking surgery and diagnostic video-assisted thoracoscopic surgery (VATS) wedge resection were subsequently done. Metastatic lesions were reported to have a histology similar to that of the original mass. VATS right upper lobectomy with mediastinal lymph node dissection was performed because of the pathology result of VATS (adenocarcinoma). She started taking an aromatase inhibitor (Letrozole(R)) and there was no evidence of recurrence of disease on an imaging study and no post-operative complications until recently.

Citations

Citations to this article as recorded by  
  • Pulmonary Benign Metastasizing Leiomyoma in a Postmenopausal Woman: A Case Report and Review of the Literature
    Aleksandra Piórek, Adam Płużański, Piotr Wiśniewski, Sylwia Tabor, Kinga Winiarczyk, Magdalena Knetki-Wróblewska, Dariusz M. Kowalski, Maciej Krzakowski
    Diseases.2024; 12(8): 181.     CrossRef
  • Benign metastasizing uterine leiomyoma with lymphatic and pulmonary metastases: a case report and literature review
    Tong Tong, Qiong Fan, Yudong Wang, Yuhong Li
    BMC Women's Health.2023;[Epub]     CrossRef
  • Pulmonary benign metastasizing uterine leiomyoma (PBML): a case report and review of the literature
    Mark R. Brincat, Sarah Lam Shang Leen, Asma Faruqi, Michail Sideris, Kelvin Kar Wing Lau, Alexandra Lawrence
    Annals of Medicine & Surgery.2023; 85(7): 3686.     CrossRef
  • Benign Metastasizing Leiomyoma of the Lung: Diagnostic Process and Treatment Based on Three Case Reports and a Review of the Literature
    Małgorzata Edyta Wojtyś, Olga Kacalska-Janssen, Konrad Ptaszyński, Piotr Lisowski, Michał Kunc, Janusz Wójcik, Tomasz Grodzki
    Biomedicines.2022; 10(10): 2465.     CrossRef
  • A case report of atypical uterine leiomyoma
    Yun Sook Kim, Hyun Joo Lee
    Medicine: Case Reports and Study Protocols.2021; 3(11): e0168.     CrossRef
  • Metastatic leiomyoma or synchronous lesion of the uteri corpus and vulva?
    I. V. Barinova, S. N. Buyanova, N. I. Kondrikov, N. A. Shchukina, I. N. Voloshchuk, M. V. Mgeliashvili, S. A. Petrakova, A. A. Aksenova
    Arkhiv patologii.2020; 82(1): 62.     CrossRef
  • Lung metastases from benign uterine leiomyoma: does 18-FDG-PET/CT have a role to play?
    Feras Abu Saadeh, Ciaran O. Riain, Ciara Mc Cormack, Noreen Gleeson
    Irish Journal of Medical Science (1971 -).2019; 188(2): 619.     CrossRef
  • Benign metastasising leiomyoma with lymph node metastases in a patient with endometrial cancer after caesarean section
    Serra Akar, Serdar Ugras, Gozde Sahin, Fatih Demir, Çetin Çelik
    Journal of Obstetrics and Gynaecology.2019; 39(3): 420.     CrossRef
  • Benign metastasizing leiomyoma presenting with miliary pattern and fatal outcome: Case report with molecular analysis & review of the literature
    Kenneth Ofori, Helen Fernandes, Matthew Cummings, Thomas Colby, Anjali Saqi
    Respiratory Medicine Case Reports.2019; 27: 100831.     CrossRef
  • Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study
    Sanam Moradan
    Journal of Menopausal Medicine.2018; 24(1): 62.     CrossRef
  • The Heart as a Site of Metastasis of Benign Metastasizing Leiomyoma: Case Report and Review of the Literature
    Mariam Meddeb, Robert D. Chow, Randolph Whipps, Reyaz Haque
    Case Reports in Cardiology.2018; 2018: 1.     CrossRef
  • BENIGN UTERUS CANCER WITH LUNG METASTASES: LEIOMYOMATOSIS, LYMPHANGIOLEIMYOMATOSIS, THORACIC ENDOMETRIOSIS (LITERATURE REVIEW, PERSONAL CLINCIAL OBSERVATIONS)
    Леншин, Anatoliy Lenshin, Ильин, Andrey Il'in, Демура, Ol'ga Demura, Крайнов, Sergey Kraynov, Побережский, Aleksey Poberezhskiy
    Bulletin physiology and pathology of respiration .2017; : 30.     CrossRef
  • Benign metastasizing leiomyoma and 18-FDG-PET/CT: A case report and literature review
    Yusuke Sawai, Toshiki Shimizu, Yuta Yamanaka, Maiko Niki, Shosaku Nomura
    Oncology Letters.2017; 14(3): 3641.     CrossRef
  • Mesothelial cell deposits in lymph nodes—a diagnostic pitfall
    Archana Pandita, Vladimir Osipov
    Annals of Diagnostic Pathology.2016; 25: 31.     CrossRef
  • Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo
    Clasina M. Venema, Giulia Apollonio, Geke A.P. Hospers, Carolina P. Schröder, Rudi A.J.O. Dierckx, Erik F.J. de Vries, Andor W.J.M. Glaudemans
    Clinical Nuclear Medicine.2016; 41(11): 844.     CrossRef
  • Single benign metastasising leiomyoma of an inguinal lymph node
    Kamil G Laban, Roberto E Tobon-Morales, Janice A L Hodge, Henk W R Schreuder
    BMJ Case Reports.2016; : bcr2016216546.     CrossRef
  • Leiomyomas beyond the uterus; benign metastasizing leiomyomatosis with paraaortic metastasizing endometriosis and intravenous leiomyomatosis: a case series and review of the literature
    Mohamad S. Mahmoud, Kavita Desai, Farr R. Nezhat
    Archives of Gynecology and Obstetrics.2015; 291(1): 223.     CrossRef
  • Benign pulmonary metastasizing leiomyoma of the uterus: A case report
    HUI MA, JIE CAO
    Oncology Letters.2015; 9(3): 1347.     CrossRef
  • Single-port laparoscopic debulking surgery of variant benign metastatic leiomyomatosis with simultaneous lymphatic spreading and intraperitoneal seeding
    Yoo Hyun Chung, Suk Woo Lee, So Young Shin, Chae Chun Rhim, Soyoung Im, Sie Hyeon Yoo, Joo Hee Yoon
    Obstetrics & Gynecology Science.2015; 58(4): 314.     CrossRef
  • Benign metastasizing leiomyoma of the lung: A case report and literature review
    WEI-TIAN WEI, PENG-CHENG CHEN
    Oncology Letters.2015; 10(1): 307.     CrossRef
  • Difficulty in complete transarterial embolization for pulmonary benign metastasizing leiomyoma with massive hemoptysis
    Masaya Miyazaki, Akie Nakayama, Daichi Noda, Yasunobu Maehara, Yoshito Tsushima
    Japanese Journal of Radiology.2014; 32(1): 53.     CrossRef
  • Pulmonary leiomyomas in a patient with bilateral renal cell cancer mimicking pulmonary metastases
    Ying-Yi Chen, Seng-Tang Wu, Hsian-Her Hsu, Ya-Cheng Chen, Shih-Chun Lee, Hung Chang, Tsai-Wang Huang
    Clinical Imaging.2014; 38(3): 330.     CrossRef
  • Incidental Benign Metastasizing Leiomyoma in a Patient with Bone Sarcoma: A Case Report
    Zanndor Jacob del Real-Romo, Carlos Montero-Cantú, Oscar Villegas-Cabello, José Antonio Díaz-Elizondo, Danae Reyes-Salas, Rene Palomo-Hoil, Guillermo Peralta-Castillo, David Martínez-Sánchez, Eduardo Flores-Villalba
    Case Reports in Surgery.2014; 2014: 1.     CrossRef
  • Metastasizing Leiomyoma to Heart
    Erin N. Consamus, Michael J. Reardon, Alberto G. Ayala, Mary R. Schwartz, Jae Y. Ro
    Methodist DeBakey Cardiovascular Journal.2014; 10(4): 251.     CrossRef
  • METASTASISING LEIOMYOMA- A CASE REPORT
    Krishna Govindan, Sheela Kuzhiveli Mohammed Ali, Lekshmy Kausthubham Sudheendran
    Journal of Evolution of Medical and Dental Sciences.2014; 7(42): 4591.     CrossRef
  • Benign Metastatic Leiomyoma Presenting as a Hemothorax
    Anna M. Ponea, Creticus P. Marak, Harmeen Goraya, Achuta K. Guddati
    Case Reports in Oncological Medicine.2013; 2013: 1.     CrossRef
  • Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review
    Erin I. Lewis, Rebecca J. Chason, Alan H. DeCherney, Alicia Armstrong, John Elkas, Aradhana M. Venkatesan
    Fertility and Sterility.2013; 99(7): 2017.     CrossRef
  • Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models
    Bosung Shim, Gustavo Pacheco-Rodriguez, Jiro Kato, Thomas N. Darling, Martha Vaughan, Joel Moss
    European Respiratory Review.2013; 22(129): 302.     CrossRef
  • Pulmonary benign metastasizing leiomyoma: a case report and review of the literature
    Yili Fu, Hui Li, Bo Tian, Bin Hu
    World Journal of Surgical Oncology.2012;[Epub]     CrossRef
  • 11,890 View
  • 71 Download
  • 29 Crossref
Close layer
Numb Chin Syndrome with Concomitant Painful Ophthalmoplegia Leading to a Diagnosis of Diffuse Large B Cell Lymphoma
Yeong-Il Kim, Jae-Young An, Kwang-Soo Lee, Hye Young Sung, Young Seon Hong, Won Kyung Kang, Chan-Kwon Jung, Joong-Seok Kim
Cancer Res Treat. 2011;43(2):134-138.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.134
AbstractAbstract PDFPubReaderePub
Painful ophthalmoplegia (PO) and concomitant numb chin syndrome (NCS) is a very rare event. There are a few reports in the literature about PO and concomitant NCS that have preceded the diagnosis of a malignancy. In this report, we describe a patient with diffuse large B cell lymphoma who presented with PO and concomitant NCS as the initial symptom of the disease.

Citations

Citations to this article as recorded by  
  • Numb chin syndrome
    Cristina Perez, Reny de Leeuw, Francisco Escala P., Rodrigo Fuentealba, Gary D. Klasser
    The Journal of the American Dental Association.2023; 154(1): 79.     CrossRef
  • Numb chin syndrome in sickle cell disease: a case series of Jamaican patients
    Zachary Ramsay, Christine Hammond Gabbadon, Monika Asnani
    Annals of Hematology.2021; 100(4): 913.     CrossRef
  • A case of paresthesia of the contralateral mental region suspected to be an early symptom of diffuse large B-cell lymphoma
    Daiki TAKAHASHI, Masaya AKASHI, Yusuke TAKAHASHI, Kazuyuki TSUJI, Tsutomu MINAMIKAWA, Takahide KOMORI
    Japanese Journal of Oral and Maxillofacial Surgery.2016; 62(4): 163.     CrossRef
  • Síndrome del mentón entumecido como manifestación de recidiva tumoral
    M. García-Lamazares, O. Ferreiro-Uriz, L. Alfaya-García
    SEMERGEN - Medicina de Familia.2014; 40(2): e43.     CrossRef
  • Primary Retroperitoneal Diffuse Large B-cell Lymphoma Presenting with Numb Chin Syndrome and Painful Ophthalmoplegia
    Satoshi Ichikawa, Kei Saito, Takuma Suzuki, Jun Kimura, Hideo Harigae
    Internal Medicine.2013; 52(16): 1813.     CrossRef
  • 11,501 View
  • 64 Download
  • 5 Crossref
Close layer
Erratum
ERRATUM: Correction for Mistyped Inequality Sign
Cancer Res Treat. 2011;43(2):139-139.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.139
AbstractAbstract PDFPubReaderePub
No abstract available.
  • 6,404 View
  • 40 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP